Fresh analysis indicates that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise regimens.
Findings released in a major medical journal shows that while obese individuals often shed substantial amounts of their total mass while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing such drugs need to be informed of the danger of quick weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight in about 18 months.
Comparing Treatments
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the results of the injectable medications with conventional dieting.
Researchers note that people who lose weight through dieting generally see a slower weight regain—around 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Experts suggest the mode of action of the injections explains the amplified rebound.
The injections mimic a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than normal could lead to the body to produce less of its endogenous hormone, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in hunger is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, given the significant potential of weight regain, the treatment might need to be life-long.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
People who have discontinued the jabs report a sudden resurgence of hunger.
"It was like a switch that goes on and you become starving," described a patient.
This difficulty is worsened if users have not developed lasting lifestyle or habit changes during therapy.
Growing Use
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females than males.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, experts emphasize that while these medications are effective agents for weight loss, they are not a permanent cure and lasting health benefits hinges on integrated behavioural changes.
